159 related articles for article (PubMed ID: 30988246)
1. Ferric Citrate Attenuates Cardiac Hypertrophy and Fibrosis in a Rat Model of Chronic Kidney Disease.
Goto M; Suematsu Y; Nunes ACF; Jing W; Khazaeli M; Lau WL; Vaziri ND
Iran J Kidney Dis; 2019 Mar; 13(2):98-104. PubMed ID: 30988246
[TBL] [Abstract][Full Text] [Related]
2. Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.
Jing W; Nunes ACF; Farzaneh T; Khazaeli M; Lau WL; Vaziri ND
J Pharmacol Exp Ther; 2018 Oct; 367(1):129-137. PubMed ID: 30093458
[TBL] [Abstract][Full Text] [Related]
3. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
[TBL] [Abstract][Full Text] [Related]
4. Route of intestinal absorption and tissue distribution of iron contained in the novel phosphate binder ferric citrate.
Vaziri ND; Nunes ACF; Said H; Khazaeli M; Liu H; Zhao Y; Jing W; Cogburn K; Alikhani L; Lau WL
Nephrol Dial Transplant; 2020 Jul; 35(7):1136-1144. PubMed ID: 32514572
[TBL] [Abstract][Full Text] [Related]
5. The Phosphate Binder Ferric Citrate Alters the Gut Microbiome in Rats with Chronic Kidney Disease.
Lau WL; Vaziri ND; Nunes ACF; Comeau AM; Langille MGI; England W; Khazaeli M; Suematsu Y; Phan J; Whiteson K
J Pharmacol Exp Ther; 2018 Dec; 367(3):452-460. PubMed ID: 30287477
[TBL] [Abstract][Full Text] [Related]
6. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
[TBL] [Abstract][Full Text] [Related]
7. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of Action and Clinical Attributes of Auryxia
Ganz T; Bino A; Salusky IB
Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
[TBL] [Abstract][Full Text] [Related]
9. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
[TBL] [Abstract][Full Text] [Related]
10. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
Nand N; Giri K; Jain D
J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
[TBL] [Abstract][Full Text] [Related]
11. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.
Hu MC; Shi M; Cho HJ; Adams-Huet B; Paek J; Hill K; Shelton J; Amaral AP; Faul C; Taniguchi M; Wolf M; Brand M; Takahashi M; Kuro-O M; Hill JA; Moe OW
J Am Soc Nephrol; 2015 Jun; 26(6):1290-302. PubMed ID: 25326585
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.
McCullough PA; Uhlig K; Neylan JF; Pergola PE; Fishbane S
Am J Cardiol; 2018 Aug; 122(4):683-688. PubMed ID: 29961562
[TBL] [Abstract][Full Text] [Related]
13. Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.
Li L; Zheng X; Deng J; Zhou J; Ou J; Hong T
Ren Fail; 2022 Dec; 44(1):1112-1122. PubMed ID: 35912897
[TBL] [Abstract][Full Text] [Related]
14. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy.
Vickery S; Price CP; John RI; Abbas NA; Webb MC; Kempson ME; Lamb EJ
Am J Kidney Dis; 2005 Oct; 46(4):610-20. PubMed ID: 16183415
[TBL] [Abstract][Full Text] [Related]
15. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
[TBL] [Abstract][Full Text] [Related]
16. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
Nakanishi T; Hasuike Y; Nanami M; Yahiro M; Kuragano T
Nephrol Dial Transplant; 2016 Oct; 31(10):1588-94. PubMed ID: 26142396
[TBL] [Abstract][Full Text] [Related]
17. Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats.
Iida A; Matsushita M; Ohta T; Yamada T
J Vet Med Sci; 2020 Mar; 82(3):379-386. PubMed ID: 31996496
[TBL] [Abstract][Full Text] [Related]
18. Copeptin Blood Content as a Diagnostic Marker of Chronic Kidney Disease.
Niemczyk S; Niemczyk L; Żmudzki W; Saracyn M; Czarzasta K; Szamotulska K; Cudnoch-Jędrzejewska A
Adv Exp Med Biol; 2018; 1096():83-91. PubMed ID: 29572679
[TBL] [Abstract][Full Text] [Related]
19. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
Hanudel MR; Laster ML; Portale AA; Dokras A; Quigley RP; Guzman GAL; Zaritsky JJ; Hayde NA; Kaskel FJ; Mitsnefes MM; Ramirez JA; Imani PD; Srivaths PR; Kogon AJ; Denburg MR; Blydt-Hansen TD; Reyes LZ; Greenbaum LA; Weidemann DK; Warady BA; Elashoff DA; Mendley SR; Isakova T; Salusky IB
Pediatr Nephrol; 2022 Nov; 37(11):2547-2557. PubMed ID: 35237863
[TBL] [Abstract][Full Text] [Related]
20. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification.
Iida A; Kemmochi Y; Kakimoto K; Tanimoto M; Mimura T; Shinozaki Y; Uemura A; Matsuo A; Matsushita M; Miyamoto K
Am J Nephrol; 2013; 37(4):346-58. PubMed ID: 23548309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
